COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.
Immunotherapy
; 12(15): 1133-1138, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-750791
ABSTRACT
Background:
Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. Case presentation A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient's discharge after 81 days of hospitalization.Conclusion:
A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Skin Neoplasms
/
Carcinoma, Merkel Cell
/
Coronavirus Infections
/
Immunotherapy
Type of study:
Case report
/
Diagnostic study
/
Etiology study
/
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Immunotherapy
Journal subject:
Allergy and Immunology
/
Therapeutics
Year:
2020
Document Type:
Article
Affiliation country:
Imt-2020-0193
Similar
MEDLINE
...
LILACS
LIS